Quick Answer
Immunocore Holdings plc reported Operating Income of -$45.35 million for fiscal year 2025.
Immunocore Holdings plc Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$45.35M | +35.6% |
| 2024 | -$70.46M | -18.1% |
| 2023 | -$59.65M | -15.4% |
| 2022 | -$51.71M | +70.4% |
| 2021 | -$174.59M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$7.17M | +15.7% | +51.8% |
| June 30, 2025 | -$14.88M | +7.1% | -311.4% |
| March 31, 2025 | -$3.62M | +86.3% | +57.5% |
| September 30, 2024 | -$8.50M | +39.9% | +46.9% |
| June 30, 2024 | -$16.02M | -16.4% | +39.5% |
| March 31, 2024 | -$26.49M | -80.3% | -87.3% |
| September 30, 2023 | -$14.14M | — | -2.8% |
| June 30, 2023 | -$13.76M | — | +6.4% |
- Immunocore Holdings plc showed an increase of +35.6% in Operating Income compared to the prior fiscal year.
- Over the 2021–2025 period, Immunocore Holdings plc’s operating income has grown by 74.0% (from -$174.59 million to -$45.35 million).
- The most recent figure is from Immunocore Holdings plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: